Blick ins Buch

Management of Castration Resistant Prostate Cancer

Fred Saad, Mario A. Eisenberger (Herausgeber)

Buch | Hardcover

337 Seiten

2014
Humana Press Inc. (Verlag)
978-1-4939-1175-2 (ISBN)

Lese- und Medienproben

Blick ins Buch (midvox)

Artikel merken

This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in depth review of proven therapeutic options, including bone targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigations are also reviewed. The text provides up to date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence based medicine.

As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy.

Fred Saad, MD, FRCS Professor and Chief of Urology, Director of GU Oncology, University of Montreal Endowed Chair in Prostate Cancer, University of Montreal Hospital Center, Department of Surgery, Division of Urology, Montreal, Quebec, Canada. Mario A. Eisenberger, MD R. Dale Hughes Professor of Oncology and Urology, The Johns Hopkins University, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.

Introduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities.- Evolution of Clinical States and the Castration Resistant Clinical Paradigm.- Molecular Mechanisms of Prostate Cancer Progression after Castration.- New Imaging Modalities.- Androgen Receptor Biology in Castration Resistant Prostate Cancer.- The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer.- Approaches Targeting Androgen Synthesis (CYP 17 inhibitors).- Cytotoxic Chemotherapy (Taxanes and Taxane Combinations).- The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer.- Bone Targeted Therapy: Rationale and Current Status.- Radium-223 and Other Radiopharmaceuticals in Prostate Cancer.- Introduction.- Phase I/II targeted treatments.- Defining Clinical Endpoints in Castration-resistant Prostate Cancer.- Angiogenesis Inhibition in Castration Resistant Prostate Cancer.- Co-targeting Adaptive Survival Pathways.- Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer.- PARP Inhibitors.- Targeting C-Met/VEGF in Castration Resistant Prostate Cancer.- Epigenetics in Castration Resistant Prostate Cancer.- Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype.- Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management.- Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development.

Reihe/Serie	Current Clinical Urology
Zusatzinfo	XVI, 337 p.
Verlagsort	Totowa, NJ
Sprache	englisch
Maße	178 x 254 mm
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
	Medizinische Fachgebiete ► Radiologie / Bildgebende Verfahren ► Radiologie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Urologie
Schlagworte	androgen receptor • immunotherapy • radiopharmaceuticals
ISBN-10	1-4939-1175-9 / 1493911759
ISBN-13	978-1-4939-1175-2 / 9781493911752
Zustand	Neuware